

Edgar Filing: TASCO HOLDINGS INTERNATIONAL, INC. - Form SC 13D

TASCO HOLDINGS INTERNATIONAL, INC.
Form SC 13D
July 10, 2006

SEC 1746 Potential persons who are to respond to the collection of
(11-02) information contained in this form are not required to respond
 unless the form displays a currently valid OMB control number.

OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response...11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

TASCO HOLDINGS INTERNATIONAL, INC.
(Name of Issuer)

Common Stock (\$0.0001 par value)
(Title of Class of Securities)

876506 20 5
(CUSIP Number)

David R. Koos, Chairman & CEO
Bio-Matrix Scientific Group, Inc.
1010 University Avenue, Suite 40
San Diego, California 92103
Telephone 619-227-9192

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

July 1, 2006
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. []

Edgar Filing: TASCO HOLDINGS INTERNATIONAL, INC. - Form SC 13D

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 876506 20 5

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).
Bio-Matrix Scientific Group, Inc., #50-0020556

2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)

3. SEC Use Only

4. Source of Funds (See Instructions) PF-OO

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization : Delaware

Number of Shares Beneficially Owned by Each Reporting Person With
7. Sole Voting Power: 10,000,000 shares of common stock (\$0.0001 par value)
8. Shared Voting Power
9. Sole Dispositive Power. 10,000,000 shares of common stock (\$0.0001 par value)
10. Shared Dispositive Power

Edgar Filing: TASCO HOLDINGS INTERNATIONAL, INC. - Form SC 13D

11. Aggregate Amount Beneficially Owned by Each Reporting Person: 10,000,000 shares of common stock (\$0.0001 par value)

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

13. Percent of Class Represented by Amount in Row (11): 78.24%

14. Type of Reporting Person (See Instructions)

CO.....
.....
.....
.....
.....

Introduction

This constitutes the Schedule 13D filed on behalf of Bio-Matrix Scientific Group, Inc., a Delaware corporation and relating to the acquisition of 10,000,000 shares of the common stock of Tasco Holdings International, Inc. acquired upon sale by Bio-Matrix Scientific Group, Inc. of its wholly-owned subsidiary, Bio-Matrix Scientific Group, Inc., a Nevada corporation (BMXG-Nevada) to Tasco Holdings International, Inc. The sale of the subsidiary to Tasco Holdings International, Inc. was accomplished solely in exchange for the sale of 25,000 shares of the common stock of the subsidiary, BMXG-Nevada. All of the disclosures set forth in the statements made in this Schedule 13D remain unchanged.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 1, 2006

Signature: /s/ David R. Koos

Edgar Filing: TASCO HOLDINGS INTERNATIONAL, INC. - Form SC 13D

Name/Title: David R. Koos, Chairman & CEO

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)